vs

Side-by-side financial comparison of Epsilon Energy Ltd. (EPSN) and SUTRO BIOPHARMA, INC. (STRO). Click either name above to swap in a different company.

Epsilon Energy Ltd. is the larger business by last-quarter revenue ($14.8M vs $11.6M, roughly 1.3× SUTRO BIOPHARMA, INC.). On growth, Epsilon Energy Ltd. posted the faster year-over-year revenue change (65.7% vs -21.4%). Over the past eight quarters, Epsilon Energy Ltd.'s revenue compounded faster (36.2% CAGR vs -5.4%).

Epsilon Composite is a French company created in 1987 by Stephane LULL, its current CEO. The company was founded in January 1987. Its production site is located in Gaillan, France. Stéphane Lull is the CEO.

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in Ja...

EPSN vs STRO — Head-to-Head

Bigger by revenue
EPSN
EPSN
1.3× larger
EPSN
$14.8M
$11.6M
STRO
Growing faster (revenue YoY)
EPSN
EPSN
+87.1% gap
EPSN
65.7%
-21.4%
STRO
Faster 2-yr revenue CAGR
EPSN
EPSN
Annualised
EPSN
36.2%
-5.4%
STRO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EPSN
EPSN
STRO
STRO
Revenue
$14.8M
$11.6M
Net Profit
$-12.4M
Gross Margin
Operating Margin
-129.0%
Net Margin
-83.9%
Revenue YoY
65.7%
-21.4%
Net Profit YoY
-1535.0%
35.4%
EPS (diluted)
$-0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EPSN
EPSN
STRO
STRO
Q4 25
$14.8M
$11.6M
Q3 25
$9.0M
$9.7M
Q2 25
$11.6M
$63.7M
Q1 25
$16.2M
$17.4M
Q4 24
$8.9M
$14.8M
Q3 24
$7.3M
$8.5M
Q2 24
$7.3M
$25.7M
Q1 24
$8.0M
$13.0M
Net Profit
EPSN
EPSN
STRO
STRO
Q4 25
$-12.4M
Q3 25
$1.1M
$-56.9M
Q2 25
$1.6M
$-11.5M
Q1 25
$4.0M
$-76.0M
Q4 24
$-760.8K
$-72.4M
Q3 24
$366.0K
$-48.8M
Q2 24
$815.7K
$-48.0M
Q1 24
$1.5M
$-58.2M
Operating Margin
EPSN
EPSN
STRO
STRO
Q4 25
-129.0%
Q3 25
6.7%
-499.9%
Q2 25
7.1%
-5.2%
Q1 25
44.3%
-393.8%
Q4 24
6.8%
-440.7%
Q3 24
3.3%
-797.2%
Q2 24
16.0%
-189.4%
Q1 24
17.6%
-435.0%
Net Margin
EPSN
EPSN
STRO
STRO
Q4 25
-83.9%
Q3 25
11.9%
-586.6%
Q2 25
13.3%
-18.0%
Q1 25
24.8%
-436.6%
Q4 24
-8.5%
-489.2%
Q3 24
5.0%
-572.6%
Q2 24
11.2%
-186.8%
Q1 24
18.9%
-447.5%
EPS (diluted)
EPSN
EPSN
STRO
STRO
Q4 25
$-0.55
Q3 25
$0.05
$-0.67
Q2 25
$0.07
$-0.14
Q1 25
$0.18
$-0.91
Q4 24
$-0.04
$-27.63
Q3 24
$0.02
$-0.59
Q2 24
$0.04
$-0.59
Q1 24
$0.07
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EPSN
EPSN
STRO
STRO
Cash + ST InvestmentsLiquidity on hand
$9.0M
$141.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$124.7M
$-132.5M
Total Assets
$228.2M
$173.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EPSN
EPSN
STRO
STRO
Q4 25
$9.0M
$141.4M
Q3 25
$12.8M
$167.6M
Q2 25
$9.9M
$205.1M
Q1 25
$6.9M
$249.0M
Q4 24
$6.5M
$316.9M
Q3 24
$8.3M
$388.3M
Q2 24
$8.6M
$375.6M
Q1 24
$2.3M
$267.6M
Stockholders' Equity
EPSN
EPSN
STRO
STRO
Q4 25
$124.7M
$-132.5M
Q3 25
$100.2M
$-87.3M
Q2 25
$100.2M
$-32.1M
Q1 25
$99.7M
$-25.8M
Q4 24
$96.7M
$44.6M
Q3 24
$98.4M
$111.2M
Q2 24
$99.6M
$152.2M
Q1 24
$99.9M
$98.0M
Total Assets
EPSN
EPSN
STRO
STRO
Q4 25
$228.2M
$173.8M
Q3 25
$126.3M
$209.7M
Q2 25
$123.6M
$262.4M
Q1 25
$125.5M
$321.4M
Q4 24
$120.5M
$387.2M
Q3 24
$121.8M
$451.8M
Q2 24
$121.1M
$489.0M
Q1 24
$125.1M
$403.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EPSN
EPSN
STRO
STRO
Operating Cash FlowLast quarter
$-277.0K
$-177.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EPSN
EPSN
STRO
STRO
Q4 25
$-277.0K
$-177.2M
Q3 25
$4.0M
$-38.2M
Q2 25
$8.3M
$-44.7M
Q1 25
$8.6M
$-67.9M
Q4 24
$5.0M
$-71.7M
Q3 24
$2.7M
$-64.5M
Q2 24
$5.4M
$9.5M
Q1 24
$3.7M
$-64.7M
Cash Conversion
EPSN
EPSN
STRO
STRO
Q4 25
Q3 25
3.70×
Q2 25
5.38×
Q1 25
2.14×
Q4 24
Q3 24
7.50×
Q2 24
6.60×
Q1 24
2.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EPSN
EPSN

Gas Oil Ngls And Condensate$13.3M90%
Gas Gathering And Compression$1.5M10%

STRO
STRO

Segment breakdown not available.

Related Comparisons